Platinum Resistant Flashcards
1
Q
Phase IIb, single-arm, open-label CONCERTO study investigating cedi + ola in non-gBRCAm pts with recurrent platinum-resistant OC who had received ≥3 previous lines of therapy for advanced OC: toxicity and RR?
A
60🧘♀️; median of 4 prior regimens;
Confirmed ORR 15.3%
Median PFS,* months 5.1
Median duration of response,*‡ months 8.3 5.6–10.3
Median overall survival, months 13.2
2
Q
Treatment Of FRα-Positive Platinum-Resistant Ovarian Cancer: FDA approval 11/2022
A
Antibody-Drug Conjugate Mirvetuximab Soravtansine
At the same time, the FDA approved the Ventana FOLR1 (FOLR1-2.1) RxDx Assay as a companion diagnostic to identify patients eligible for mirvetuximab.”
